News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Keryx Biopharmaceuticals (KERX) Announces First Quarter 2014 Financial Results



5/8/2014 9:31:11 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, May 8, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients suffering from renal disease (the "Company"), today announced its financial results for the first quarter ended March 31, 2014. In the first quarter, Keryx raised approximately $107.6 million, net of underwriting discounts and offering expenses, through an underwritten public offering of common stock, ending the quarter with $155.1 million of cash, cash equivalents, short-term investments and interest receivable, and no debt.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES